Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

Mr Mohammad Abul Qasem

22 Apr 2014 07:01

RNS Number : 1619F
Beximco Pharmaceuticals Ltd
22 April 2014
 



BEXIMCO PHARMACEUTICALS LTD.

 

 

22nd April, 2014

 

 

Mr Mohammad Abul Qasem

 

Beximco Pharmaceuticals Limited (or "the Company"; LSE-AIM: BXP) announces with sadness the death of Mohammad Abul Qasem, a Director of the Company, on 19 April 2014.

 

Ahmed Sohail Fasiur Rahman, Chairman of Beximco Pharmaceuticals, said: "The Board of Directors recall with appreciation and gratitude Mohammad Abul Qasem's contribution towards the establishment and growth of Beximco Pharmaceuticals Ltd. The Beximco Pharma Family extends their deepest sympathy and sincerest condolences to the bereaved members of his family at his sad demise."

 

 

For further information please visit www.beximco-pharma.com or enquire to:

 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.20080

 

Daniel Stewart & Company (NOMAD and Broker)

Emma Earl

James Thomas

Tel: +44 (0)20 7776 6550

 

FTI Consulting

Simon Conway/ Victoria Foster-Mitchell

Tel: +44 (0)20 3727 1000

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.

 

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIBMRTMBMTBBI
Date   Source Headline
4th May 20107:01 amRNSSecond Preference Share Conversion
4th May 20107:00 amRNSFinal Results
29th Apr 201012:44 pmRNSPrice Sensitive Information
1st Feb 20109:15 amRNSFirst Preference Share Conversion
11th Jan 20101:36 pmRNSPlacing and Strategic Update
26th Nov 20097:00 amRNS3rd Quarter Results
22nd Oct 20092:32 pmRNSIssuance of Preference Shares
19th Oct 20099:21 amRNSClarification Re Preference Share Issue
15th Oct 20091:58 pmRNSEGM Statement
10th Sep 20094:33 pmRNSNotice of EGM
3rd Sep 20097:00 amRNSResult of Meeting
30th Jul 20097:00 amRNSHalf Year Results
18th Jun 200912:01 pmRNSAGM Statement
20th May 20097:00 amRNSExport agreement to Latin and Central America
14th May 20097:00 amRNSNotice of AGM
7th May 200910:00 amRNSFinal Results
30th Apr 200912:55 pmRNSPrice Sensitive Information
5th Mar 200910:44 amRNSSEC Consent to GEM Placing
19th Feb 20097:00 amRNSEGM Statement
27th Jan 20091:14 pmRNSPrivate Placing to GEM Global Yield Fund Limited
26th Jan 20097:58 amRNSBoard Meeting Update
14th Nov 20087:00 amRNSGulf Export Approval
9th Sep 20087:00 amRNSChile Exports
28th Aug 20081:50 pmRNSRe: Salman Rahman
31st Jul 20087:00 amRNSInterim Results
22nd Jul 20087:00 amRNSRe: Approval
12th May 20086:00 amRNSFinal Results
6th May 200810:58 amRNSNotice of AGM - Amendment
6th May 200810:15 amRNSNotice of AGM
25th Oct 200710:16 amRNSCommences Exports to Fiji
28th Sep 20077:01 amRNSRe: Exports to Jordan
10th Sep 20078:33 amRNSExports to Philippines
30th Aug 20072:22 pmRNSRe: Exports to Hong Kong
16th Aug 200712:10 pmRNSRe: AIM Rule 26
1st Aug 20079:00 amRNSInterim Results
29th Jun 20077:03 amRNSFinal Results
29th May 20071:36 pmRNSRe: Exports
30th Apr 200712:13 pmRNSExports to Middle East
2nd Apr 20077:01 amRNSRe: Exports to Ghana
22nd Mar 20077:00 amRNSCommences Exports to Belize
14th Mar 20078:02 amRNSExports to Botswana Commenced
22nd Feb 20077:01 amRNSTrading Statement
12th Feb 20073:51 pmRNSDetention of Salman Rahman
20th Dec 20067:00 amRNSTrading update
10th Oct 200611:45 amRNSOSD Plant Update
21st Sep 20062:32 pmRNSProduct Development
31st Jul 20067:02 amRNSInterim Results
9th Jun 200612:16 pmRNSLaunches Bird Flu Drug
31st May 20063:20 pmRNSRe Fundraising
2nd May 20067:03 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.